Drug Profile

Recombinant human laminin 111 - Prothelia

Alternative Names: LAM-111; Recombinant human laminin-111; rhLAM-111

Latest Information Update: 27 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Nevada Reno
Developer Prothelia; Sarcomatrix Therapeutics
Class Recombinant proteins
Mechanism of Action Laminin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Muscular dystrophies; Duchenne muscular dystrophy
New Molecular Entity No

Highest Development Phases

Preclinical Muscular dystrophies
No development reported Duchenne muscular dystrophy

Most Recent Events

27 Sep 2023 Preclinical development is ongoing in Muscular dystrophies in USA (IV) (Sarcomatrix Therapeutics pipeline, September 2023)
28 Feb 2023 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com